Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,337,824

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,337,824 protect, and when does it expire?

Patent 8,337,824 protects VELTASSA and is included in one NDA.

This patent has seventy-two patent family members in twenty-five countries.

Summary for Patent: 8,337,824
Title:Linear polyol stabilized polyfluoroacrylate compositions
Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
Inventor(s): Albrecht; Detlef (Saratoga, CA), Burdick; Michael (Los Altos, CA), Chang; Han-Ting (Livermore, CA), Charmot; Dominique (Campbell, CA), Chidambaram; Ramakrishnan (Pleasanton, CA), Connor; Eric (Los Gatos, CA), Halfon; Sherin (Palo Alto, CA), Huang; I-Zu (Mountain View, CA), Liu; Mingjun (Campbell, CA), Mills; Jonathan (San Jose, CA), Struver; Werner (Leverkusen, DE)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/545,810
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,337,824
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 8,337,824

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF HYPERKALEMIA ⤷  Try it Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF HYPERKALEMIA ⤷  Try it Free
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y TREATMENT OF HYPERKALEMIA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,337,824

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009282721 ⤷  Try it Free
Brazil PI0917853 ⤷  Try it Free
Canada 2735058 ⤷  Try it Free
China 102202670 ⤷  Try it Free
China 103919792 ⤷  Try it Free
Cyprus 1116850 ⤷  Try it Free
Cyprus 1120930 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.